Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas

Sarmanova, Jana

doi:10.1093/hmg/10.12.1265

Cited by 78 publications

(66 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a significant increase in *1/*5 genotype in both the AML (OR ¼ 3.9) and ALL (OR ¼ 3.6) groups. CYP2E1 variants have been found to be associated with the susceptibility to several cancers such as colorectal [39], lung [40,41], stomach [42], lymphoma [23], and acute lymphoblastic leukemia [36,43]. CYP2E1 gene RsaI polymorphism in the 5 0 flanking (promoter) region affects its transcriptional activity [44].…”

Section: Discussionmentioning

confidence: 99%

Role ofCYP2D6, CYP1A1, CYP2E1, GSTT1, andGSTM1 genes in the susceptibility to acute leukemias

Sayitoğlu¹,

Hatırnaz²,

Erensoy³

et al. 2006

Am. J. Hematol.

101

View full text Add to dashboard Cite

Acute leukemias (ALs) are heterogeneous diseases. Functional polymorphisms in the genes encoding detoxification enzymes cause inter-individual differences, which contribute to leukemia susceptibility. The CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 polymorphisms in ALL (n = 156) and AML (n = 94) patients and 140 healthy controls were genotyped by PCR and/or PCR-RFLP using blood or bone marrow samples. No association was observed between the GSTT1 gene deletion and patients (OR = 0.8, 95% CI = 0.4-1.7 for AMLs and OR = 0.9, 95% CI ¼ 0.5-1.6 for ALLs). Patients with ALL and AML had a higher prevalence of the GSTM1 deletions compared to controls but only the difference among adult AML patients (OR = 2.1, 95% CI = 1.0-4.2) was statistically significant. The CYP2D6*3 variant allele frequency was lower in the overall acute leukemia patients (0.6%) compared to controls (P = 0.03). CYP2D6*1/*3 genotype frequency also showed a protective association in AML patients (OR = 0.09, 95% CI = 0.01-1.7; P = 0.04). We also found a risk association for CYP2E1*5 in ALL and AML (OR = 3.6, 95% CI = 1.4-9.4 and OR = 3.9, 95% CI = 1.4-10.5, respectively). No association was found for the studied CYP2D6*4, CYP1A1*2A, and GSTT1''null'' variants and the risk of acute leukemia (ALL or AML). This case-control study suggests a contribution of CYP2E1, CYP2D6, and GSTM1 ''null'' variants to the development of acute leukemias. Am.

show abstract

Section: Discussionmentioning

confidence: 99%

Role ofCYP2D6, CYP1A1, CYP2E1, GSTT1, andGSTM1 genes in the susceptibility to acute leukemias

Sayitoğlu¹,

Hatırnaz²,

Erensoy³

et al. 2006

Am. J. Hematol.

101

View full text Add to dashboard Cite

show abstract

“…Sarmanova et al conducted a study in Prague, Czech Republic, of 143 non-Hodgkin's lymphoma cases and 455 populationbased controls (21,22). They did not observe any association with the risk of non-Hodgkin's lymphoma for the CYP2E1 À1054C>T variant.…”

Section: Discussionmentioning

confidence: 99%

Metabolic Gene Variants and Risk of Non-Hodgkin's Lymphoma

Roos

Gold

Wang

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Genes involved in metabolism of environmental chemical exposures exhibit sequence variability that may mediate the risk of non-Hodgkin's lymphoma. We evaluated associations between non-Hodgkin's lymphoma and 15 variants in AHR, CYP1A1, CYP1A2, CYP1B1, CYP2C9, CYP2E1, GSTP1, GSTM3, EPHX1, NQO1, and PON1. Cases were identified from four Surveillance, Epidemiology, and End Results registries in the United States, and population-based controls were identified through random-digit dialing and Medicare eligibility files. Metabolic gene variants were characterized for the 1,172 (89% of total) cases and 982 (93%) controls who provided biological samples for genotyping. Subjects who were heterozygous or homozygous for the cytochrome P450 gene variant CYP1B1 V432L G allele were at slightly greater risk of non-Hodgkin's lymphoma [odds ratio (OR), 1.27; 95% confidence interval (95% CI), 0.97-1.65]; these results were consistent across B-cell lymphoma subtypes and among both non-Hispanic White and Black subjects, although not statistically significant. The CYP2E1 À1054T allele was associated with decreased risk of non-Hodgkin's lymphoma (CT and TT genotypes combined OR, 0.59; 95% CI, 0.37-0.93), and this pattern was observed among all histologic subtypes. The numbers of cases of particular subtypes were rather small for stable estimates, but we noted that the PON1 L55M AA allele, associated with slightly increased risk of nonHodgkin's lymphoma (variant homozygotes OR, 1.36; 95% CI, 0.96-1.95), was most strongly associated with follicular nonHodgkin's lymphoma and T-cell lymphoma, with ORs for variant homozygotes of 2.12 and 2.93, respectively. There was no overall association with non-Hodgkin's lymphoma for the other gene variants we examined. The modest effects we observed may reflect the context of exposures within the general population represented in our study. (Cancer Epidemiol Biomarkers Prev 2006;15(9):1647 -53)

show abstract

“…487,488 Several genetic association studies of biotransformation enzymes, which detoxify or activate xenobiotic substances, have not yielded consistent findings, although polymorphisms in some genes have variously been associated with NHL. [489][490][491][492][493] In general, single reports of genetic associations should be interpreted cautiously; rather, large genetic studies with standardized methods are needed for validation and synthesis of results.…”

Section: Genetic Variationmentioning

confidence: 99%